GHK-Cu vs SS-31

GHK-Cu and SS-31 represent two distinct approaches to anti-aging research. GHK-Cu, a naturally occurring copper-binding tripeptide, has a long history in cosmetic and wound-healing studies, with a well-established safety profile. SS-31, a synthetic mitochondria-targeted tetrapeptide, is a newer candidate undergoing clinical trials for mitochondrial dysfunction and cardiac conditions. This comparison explores their mechanisms, evidence bases, dosing considerations, and safety profiles, highlighting key overlaps and divergences to guide informed research decisions.

GHK-Cu (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide that binds copper and is found in human plasma, saliva, and urine. Discovered by Dr. Loren Pickart in 1973, its plasma levels decline with age—from an average of 200 ng/mL at age 20 to approximately 80 ng/mL by age 60. Research suggests GHK-Cu modulates gene expression, promoting collagen synthesis, wound healing, and skin regeneration. With decades of cosmetic use and a broad safety profile, it has been extensively studied for skin firmness, elasticity, and reducing fine lines and wrinkles. Its molecular weight is approximately 340 g/mol as the copper complex (formula C14H24N6O4Cu).

SS-31 (Elamipretide) is a synthetic tetrapeptide designed to target mitochondria. It selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin and stabilizing cristae structure. This action is thought to improve mitochondrial function, particularly in conditions like heart failure and Barth syndrome. Developed by Stealth BioTherapeutics, SS-31 has undergone multiple Phase I–III clinical trials, including the TAZPOWER trial for Barth syndrome. Studies indicate potential benefits in reducing cardiac dysfunction and age-related mitochondrial decline, though its anti-aging applications remain under investigation.

Both GHK-Cu and SS-31 are investigated for anti-aging research, but their applications diverge significantly. GHK-Cu is primarily studied in the context of skin health and wound healing, leveraging its ability to promote collagen synthesis and tissue repair. In contrast, SS-31 is researched for metabolic health, focusing on mitochondrial bioenergetics and cardiac function. This distinction reflects their different mechanisms: GHK-Cu targets extracellular matrix remodeling, while SS-31 addresses intracellular energy production.

GHK-Cu has an excellent safety profile, with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520). Topical forms are generally well-tolerated; mild skin irritation is rare and typically limited to very sensitive skin. Injectable forms may cause mild injection site reactions, lightheadedness, nausea, or flu-like symptoms; rotating injection sites can reduce local irritation. SS-31 is generally well-tolerated in clinical trials at tested doses, with common side effects including injection site reactions (pain, redness), mild headache, dizziness, and nausea. Researchers should monitor for these effects in study protocols.